Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?

Data de publicação:

Autores da FMUP

  • João Pedro Melo Marques Pinho Ferreira

    Autor

Participantes de fora da FMUP

  • MENDONÇA L.U.Í.S.
  • NEVES J.S.

Unidades de investigação

Abstract

[No abstract available]

Dados da publicação

ISSN/ISSNe:
1071-9164, 1532-8414

Journal of Cardiac Failure  Churchill Livingstone

Tipo:
Article
Páginas:
1181-1182
Link para outro recurso:
www.scopus.com

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; dapagliflozin; sacubitril plus valsartan; semaglutide; sodium glucose cotransporter 2 inhibitor; vericiguat; glucagon like peptide; semaglutide; adverse outcome; all cause mortality; Article; cardiovascular mortality; chronic kidney failure; drug efficacy; drug safety; estimated glomerular filtration rate; follow up; heart failure; heart failure with reduced ejection fraction; human; kidney disease; kidney function; kidney transplantation; mortality rate; non insulin dependent diabetes mellitus; renal replacement therapy; risk reduction; complication; drug therapy; non insulin dependent diabetes mellitus

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023

Citar a publicação

Partilhar a publicação